Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Compugen ( (CGEN) ) has provided an update.
On May 13, 2025, Compugen Ltd. announced significant leadership transitions effective September 2025. Anat Cohen-Dayag, Ph.D., will become Executive Chair of the Board, and Eran Ophir, Ph.D., will assume the roles of President and CEO, succeeding Paul Sekhri as Chair. These changes are expected to strengthen Compugen’s strategic direction and operational leadership, as the company continues to advance its innovative immuno-oncology pipeline and strategic collaborations. The leadership transition aims to build on the company’s solid foundation and ensure continued growth and innovation in the field of cancer immunotherapy.
The most recent analyst rating on (CGEN) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.
Spark’s Take on CGEN Stock
According to Spark, TipRanks’ AI Analyst, CGEN is a Neutral.
Compugen’s overall score reflects its challenging financial performance typical in biotechnology, with fluctuating revenues and profitability issues. Technical indicators show bearish trends, while valuation metrics highlight risks. The earnings call provides some optimism with strategic advancements and financial stability, but ongoing net losses and revenue declines pose challenges.
To see Spark’s full report on CGEN stock, click here.
More about Compugen
Compugen is a clinical-stage therapeutic discovery and development company that utilizes its predictive computational discovery platform, Unigen, to identify new drug targets and biological pathways for cancer immunotherapies. The company has proprietary product candidates in various stages of development, including COM701 and COM902, and collaborates with partners like AstraZeneca and Gilead. Compugen is headquartered in Israel and has offices in San Francisco, with shares listed on Nasdaq and the Tel Aviv Stock Exchange under the symbol CGEN.
Average Trading Volume: 282,347
Technical Sentiment Signal: Sell
Current Market Cap: $123.4M
For a thorough assessment of CGEN stock, go to TipRanks’ Stock Analysis page.